Abstracts A127 more economically effective alternative drug but it can be used only as second or third line of treatment with biological drugs according to Russian standards of rheumatoid arthritis' management. OBJECTIVES: This study seeks to compare the cost-effectiveness of bisphosphonates for the treatment and prevention of post-menopausal osteoporosis (PMO). METHODS: A literature review was conducted to obtain all relevant articles published through the end of 2009 that evaluate the cost-effectiveness of bisphosphonates for the treatment and prevention of PMO. PubMed and the Cochrane Database were used to search for the terms "bisphosphonates" and "cost-effectiveness." Articles were limited to those evaluating at least one of the four products with an indication approved by the United States Food and Drug Administration for PMO: alendronate, ibandronate, risedronate, or zoledronic acid. Articles focusing on screening efforts, or evaluating the treatment of men, glucocorticoid-induced osteoporosis, or cancer-related bone complications were excluded. A manual review of the included articles' references was also performed. RESULTS: The literature search resulted in 189 articles of which 18 met the criteria for inclusion in this evaluation. Of these 18 studies, many examined the use of more than one bisphosphonate, therefore, the total number of comparisons identified for alendronate, ibandronate, risedronate, and zoledronic acid were 13, 3, 8, and 1, respectively. The incremental costeffectiveness ratios obtained from this analysis varied greatly for all included agents: alendronate ranged from −$25,296.12 (cost-savings) to $934,883.71; ibandronate from $10, 354.68 to $15,023.90; risedronate from $1,468.75 to $241,410.15; and zoledronic acid from $1,791.42 to $2,205.39. These results varied based on the included women's age and underlying risk factors, the specific costs accounted for in each analysis, and the total duration of treatment. CONCLUSIONS: Bisphosphonates represent cost-effective treatment options for the prevention and treatment of PMO. Given the evidence available, it is difficult to determine whether one agent is conclusively more cost-effective than another for this indication. Further studies directly comparing bisphosphonates should be conducted to evaluate their comparative cost-effectiveness.
patients suffering from this debilitating condition. This study seeks to quantify hospital costs associated with vertebroplasty and kyphoplasty. METHODS: Analysis of hospital discharge and billing records extracted from the Premier Perspective™ database, [2007] [2008] . The Premier database contains clinical and financial information from over 600 hospitals. Independent-sample t tests were used to test for between-group differences in total and department-specific direct medical costs incurred during the index inpatient or outpatient procedure. RESULTS: A total of 3617 patients received vertebroplasty (64% inpatient and 36% outpatient) and 8,118 received kyphoplasty (54% inpatient and 46% outpatient) for treatment of VCF. Patients in the vertebroplasty group had a mean age of 78, and patients in the kyphoplasty group had a mean age of 76. More patients in the vertebroplasty group (14.5%) had an APR-severity rating of "major" or "extreme" than patients in the kyphoplasty group (9.5%). Mean total inpatient costs were $9,837 for vertebroplasty compared to $13,187 for kyphoplasty (p < 0.0001). Mean total outpatient costs were $3,319 for vertebroplasty compared to $8,100 for kyphoplasty (p < 0.0001). Adjustments to control for differences in age, sex, admission status, and disease severity accentuate these differences. CONCLUSIONS: Compared to kyphoplasty, vertebroplasty is a cost-minimizing option for treatment of VCF, reducing hospital costs by nearly $5000 for outpatient procedures and by more than $3000 for inpatient procedures. These differences occurred despite older age and greater disease severity for patients in the vertebroplasty group. Further research is necessary to evaluate the incremental cost effectiveness of treatment options for VCF.
PMS27 THE COMMON PRACTICE OF ANTI-TNF PRESCRIPTION AND DISPENSING CONDITIONS
Andrieu S 1 , Ripert M 2 , Meunier N 2 , Camara Raynaud C 3 1 Cegedim, Boulogne, France, 2 Wyeth, Paris La défense, France, 3 Wyeth, Paris la Défense, France OBJECTIVES: The objective was to compare Etanercept and Adalimumab in terms of adequacy of recommended indications and of the health care costs. METHODS: This survey of cost minimization was performed by an office based pharmacist panel answering to a questionnaire at the moment of the delivery of one among two ambulatory biologics, Etanercept and Adalimumab. RESULTS: The results show that these biologics are mainly prescribed in rheumatology, 94% and 79% for Etanercept and Adalimumab respectively. The prescriptions are consistent with recommended indications for both products. In rheumatology, the retailing of consumption by pathology is closed for the two treatments. The follow of treatment scheme and of the associated costs have been realized only for the adult rheumatologic indications. At 93.8%, "Etanercept 50 mg" is prescribed at the recommended dosage. In 2.2 % of cases, the dosage increased at two injections per week and decreased at one injection all 2 weeks in 2.5 % of cases. For Adamimumab, 82.6 % treatments followed the recommended dosage, 3.6 % at an inferior dosage and 13.8 % at a superior dosage with one or two injections per week. The differential between the recommended treatment scheme and the common practice have a direct impact on the annual treatment cost. The health care costs with Etanercept appeared less expensive. The mean annual cost per patient is of 312,566 with Etanercept and of 316,252 with Adalimumab. CONCLUSIONS: This survey demonstrates that the health care cost is 29% superior with Adalimumab. The health care with Etanercept seems to have a better stability of the recommended treatment scheme.
PMS28

COST-UTILITY ANALYSIS OF TUMOR NECROSIS FACTOR-ALPHA INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS USING A MARKOV MODEL
Nguyen CM, Mendes M, Bounthavong M, Christopher M, Morreale AP Veterans Affairs San Diego Healthcare System, San Diego, CA, USA OBJECTIVES: To determine which tumor necrosis factor-alpha (TNF-alpha) inhibitor is the most cost-effective agent for the treatment of rheumatoid arthritis. METHODS: A Markov model was designed to analyze the cost-utility of certolizumab, etanercept, adalimumab and golimumab versus infliximab (with methotrexate) for the treatment of moderately to severely active rheumatoid arthritis from a U.S. health care payer perspective. A cohort of 10,000 patients was simulated using half-cycle correction with a cycle length of three months for a total of five years. The probability of achieving ACR70, serious infections, and hospitalization were based on data from published literature and assumed to follow a beta distribution. Utility scores were based on a published report using a visual analog scale. Costs were adjusted for 2009 U.S. dollars using the medical consumer price index and a discount rate of 3% per annum. Cost and utility scores were assumed to follow a gamma distribution. Probabilistic sensitivity analysis (PSA) was performed to test the robustness of the base-case model. RESULTS: Certolizumab, etanercept, adalimumab and golimumab were dominant compared to infliximab with incremental cost-effectiveness ratios (ICERs) of −$101,377.60, −$137,606.34, −$102,689.18, and −$63,415.60/additional QALY gained, respectively. The cost-effectiveness ratios of certolizumab, etanercept, adalimumab, golimumab, and infliximab were $6325.62, $6467.41, $6595.43, $6903.74, and $7508.16, respectively. Certolizumab resulted in the lowest cost and highest gain in QALYs compared to all comparators. In the PSA, there was a higher proportion of ICERs that were cost-effective with certolizumab (91.06%), etanercept (85.89%), adalimumab (84.67%), and golimumab (79.23%) when compared to infliximab at a willingness-to-pay (WTP) of $60,000. The acceptability curve showed that certolizumab had a higher probability of being cost-effective compared to all other comparators at a WTP of $60,000/additional QALY gained. CONCLUSIONS: At a $60,000 WTP threshold, certolizumab may be the most cost-effective agent for the treatment of rheumatoid arthritis compared to all other TNF-alpha inhibitors. (MTX) . OBJECTIVES: To determine the cost-effectiveness of abatacept compared to other biologics in the treatment of moderate-to-severe active RA in patients with inadequate response to MTX in Canada. METHODS: An existing USbased cost-effectiveness model was adapted to the Canadian setting. The techniques of dynamic simulation were employed to estimate the impact of abatacept and other biologics on functional disability (expressed in patients' Health Assessment Questionnaire (HAQ) scores) and clinical and economic outcomes. The model focuses on a hypothetical cohort of patients, simulating their disability quarterly over 1, 5, 10 years and lifetime. First-order simulation was conducted to gauge the influence of individual input parameters. Second-order Monte Carlo simulation was performed to examine the overall effect of uncertainty in the model. Efficacy data were based on a separate meta-analysis. The perspective adopted was that of a provincial ministry of health. Utility data were obtained from a study that mapped Health Utility Index values on a Canadian RA population. Costs (2009 CAD) and outcomes were discounted at 5% annually. RESULTS: Abatacept has a cost-effectiveness ratio of approximately $93,000 per QALY gained vs. MTX, comparable with those of etanercept ($96,000) and adalimumab ($112,000) and much lower than that of infliximab ($171,000). At willingness-to-pay between $80,000 and $97,000, abatacept is the most cost-effective option. Results were most sensitive to the assumption of the threshold for clinically meaningful HAQ improvement at 6-month and applied time horizon. CONCLU-SIONS: Determination of an appropriate biological therapy in RA depends on multiple factors including economic value. Abatacept offers a valuable therapeutic option for the treatment of moderate-to-severe active RA in patients with inadequate response to one or more DMARD therapies.
PMS29 CANADIAN COST-EFFECTIVENESS ANALYSIS OF ABATACEPT (ORENCIA TM ) FOR THE MANAGEMENT OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE
PMS30 ADHERENCE TO DULOXETINE AND HOSPITAL UTILIZATION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND CHRONIC PAIN
Wang J 1 , Liu X 2 , Mullins CD 3 1 The University of Tennessee, Memphis, TN, USA, 2 Eli Lilly and Company, Indianapolis, IN, USA, 3 The University of Maryland, Baltimore, MD, USA OBJECTIVES: Duloxetine, a serotonin and norepinephrine reuptake inhibitor, has been approved for the treatment of both major depressive disorder (MDD) and certain chronic pain-related diseases (CPD). This study examined the association between adherence to duloxetine and hospital utilization among MDD patients with CPD. METHODS: This is a retrospective cohort study analyzing data from the MarketScan commercial databases. Patients were included in the analyses if they used duloxetine during the index period of July 1, 2006-June 30, 2007 and had no record of duloxetine use during a 3-month washout period. Inclusion criteria required MDD diagnosis and at least one CPD of interest (fibromyalgia, diabetes with neurological manifestations, low back pain, headache, and osteoarthritis). Patients were followed up 12 months after index date. Adherence was defined as medication possession ratio (MPR) of 80% or higher. Hospital utilization included emergency room visits and hospitalizations. Psychiatric hospitalizations were based on principal diagnosis codes for admissions. Logistic regression and negative binomial regression models were used to adjust for patient characteristics. RESULTS: Compared to those with MPR < 80% (n = 2,988), patients adherent to duloxetine (n = 2,589) had fewer emergency room visits (1.51 vs. 2.07; p < 0.0001), lower likelihood of emergency room visit (36.85% vs. 41.57%; p = 0.0003), fewer all-cause hospitalizations (0.34 vs. 0.46; p < 0.0001), fewer psychiatric hospitalizations (0.10 vs. 0.15; p < 0.0001), fewer all-cause hospitalization days (1.46 vs. 2.43; p < 0.0001), fewer psychiatric hospitalization days (0.53 vs. 1.04; p = 0.0001), lower likelihood of hospitalization for any cause (20.97% vs. 25.07%; p = 0.0003) and lower likelihood of psychiatric hospitalization (6.80% vs. 8.97%; p = 0.0028). These differences were essentially the same after adjusting for patient characteristics. CONCLUSIONS: Adherence to duloxetine was associated with lower hospital utilization among MDD patients with CPD, suggesting the importance of improving patient adherence to duloxetine. Future studies should examine whether the lower hospital utilization associated with duloxetine adherence translates to lower costs.
MUSCULAR-SKELETAL DISORDERS -Patient-Reported Outcomes Studies
PMS31 AN EVENT-LEVEL ANALYSIS OF PRESCRIPTION REFILL INTERVALS FOR ADALIMUMAB AND ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Rizzo J 1 , Gunnarsson C 2 , Fang H 3 , Carter C 4 , Bolge S 4 , McKenzie RS 4 1 Stony Brook University, Stony Brook, NY, USA, 2 S2 Statistical Solutions Inc, Cincinnati, OH, USA, 3 U of Colorado at Boulder, Aurora, CO, USA, 4 Centocor Ortho Biotech Services, LLC, Horsham, PA, USA OBJECTIVES: To assess differences in rates of shorter, longer, and on-time prescription refill intervals for adalimumab and etanercept in rheumatoid arthritis (RA) and to identify factors associated with rates of longer prescription refill intervals. METHODS: An event-level analysis was conducted using medical/pharmacy claims from a database of 98 managed care plans. Inclusion criteria included index tumor necrosis factor inhibitor (anti-TNF) started January 2004-December 2007, patient age ≥18, 2 RA diagnosis codes (ICD-9 code 714.xx), and 365 days of index anti-TNF treatment. Patients with selected other inflammatory conditions or evidence of anti-TNFs during 6 months prior to index date or abatacept or rituximab while on index anti-TNF were excluded. Prescription refill intervals were assessed by comparing the observed time between dates of prescription claims with recommended dosing frequency in prescribing information (i.e., adalimumab = 14 days, etanercept = 7 days). Observed refills within seven days of the recommended dosing frequency were considered "on time"; intervals greater than seven days "longer"; and less than seven days "shorter". Multivariable logistic regression analyses were performed to examine determinants of longer refill intervals. RESULTS: There were 26,103 prescription refill events for adalimumab (N = 1,279 patients), and 48,859 for etanercept (N = 2,277 patients). Rates of shorter refill intervals were low: 3.7% for adalimumab and 3.5% for etanercept. Longer and on-time refill interval rates were comparable for adalimumab (27.4% and 68.9%) and etanercept (29.5% and 67.0%), respectively. Regression analyses revealed etanercept longer intervals increased with duration of use (p < 0.01), female gender (p < 0.01), and lack of insurance (p < 0.01), but decreased with older age (p < 0.01). A similar pattern emerged for adalimumab. CONCLUSIONS: More than one in four of all adalimumab and etanercept prescription refill events in RA had longer refill intervals than recommended. Further research is warranted assessing the clinical and economic consequences of delays in prescription refills, which may be suggestive of under-dosing.
PMS32
ANTI-TUMOR NECROSIS FACTOR SWITCHING, DISCONTINUATION, AND PERSISTENCE IN MANAGED CARE PATIENTS WITH RHEUMATOID ARTHRITIS
Buysman E 1 , Tang B 2 , Carter C 2 , Piech CT 2 1 I3 Innovus, Eden Prairie, MN, USA, 2 Centocor Ortho Biotech Services, LLC, Horsham, PA, USA OBJECTIVES: To evaluate switching, discontinuation, and persistence among patients with RA receiving anti-TNFs. METHODS: This was a retrospective cohort study of RA patients, in a large managed care database, using their first anti-TNF January 1, 2005 -June 30, 2006. Patients were required to have ≥30 months of continuous plan eligibility: 6 months prior to and 24 months following their index anti-TNF date, and no evidence of pre-index biologic use. For patients with index adalimumab (ADA) or etanercept (ETA), a gap in days' supply exceeding 60 days (i.e., no fills between prescription fill dates and prescription fill date + days supply + 60) indicated discontinuation. For patients with index infliximab (IFX), a gap in medical claims for infusions >8 weeks + 60 days indicated discontinuation. Switching was defined as use of a new biologic post-index. Persistence was defined as continuous use of index anti-TNF without discontinuation or switching. Differences in switching, discontinuation, and persistence rates were evaluated.RESULTS: A total of 1780 patients were analyzed: ADA = 601 (33.8%); ETA = 785 (44.1%); IFX = 394 (22.1%). Over threequarters (77%) were female; mean age was 50.1 years. IFX patients were older and had a higher Charlson-Quan comorbidity score than ADA or ETA patients. Each treatment group experienced switching (ADA = 13.1%, ETA = 11%, IFX = 13.5%). The IFX group had the lowest rate of discontinuation (37.6%) and greatest persistence (49%) compared to ADA (57.2% discontinuation, 29.6% persistence; p < 0.0001 for both) or ETA (57.5% discontinuation, 31.6% persistence; p < 0.0001 for both). CONCLUSIONS: These results indicate that among RA patients receiving anti-TNFs, the portion that switch does not vary by treatment in the 2 years following start of therapy. However, differences in discontinuation and persistence were noted. Studies are needed to investigate reasons for and impact of discontinuation and persistence on clinical and economic outcomes.
PMS33 PARTICIPATION, SATISFACTION AND KNOWLEDGE LEVEL AMONG PSORIATIC ARTHRITIS AND CUTANEOUS PSORIASIS PATIENTS
Tabolli S, di Pietro C, Renzi C IDI IRCCS Rome, Rome, Italy OBJECTIVES: To examine attitudes and satisfaction with decision-making among psoriatic arthritis (PA) patients, comparing them with cutaneous psoriasis (CP) patients. A further aim was to analyse factors associated with patients preferring an active participation and patient satisfaction. METHODS: A questionnaire was selfcompleted after a routine medical visit by a consecutive sample of 231 psoriasis patients, including 33 PA patients. The questionnaire was based on previously pub-
